NewsMonday, 19. July 2010
PARI SINUS and dornase alfa: an efficient tandem team in treating chronic rhinosinusitis
The average participant age was 22 years in the randomized, placebo controlled cross-over study. Patients were randomly assigned to two treatment groups. The first group received dornase alfa via PARI SINUS for 28 days, the second group a placebo treatment. After a 4 week washout period, patients crossed over to the other group.
Quality of life was assessed with a standardised questionnaire at baseline and at the end of each treatment period. Symptoms and lung function were also evaluated. All parameters significantly improved during therapy with dornase alfa via PARI SINUS compared to placebo treatment. The therapy was well tolerated and no severe adverse events occurred.
These results were presented at this year’s European cystic fibrosis conference in Valencia. The workgroup led by Jochen Mainz (PHD) from Jena, Germany, concluded: “Even in the short period of 4 weeks of treatment the new method of sinonasal inhalation of dornase alfa led to significant reduction of sinonasal symptoms in CF-patients”.
Whereas the nose is easily reached with simple nasal sprays or irrigations, therapy for the paranasal sinuses poses much more of a problem. The “gate” into these cavities is very narrow and fluids or aerosol administered conventionally are unable to gain access. The PARI SINUS is a groundbreaking device, which sends a pulsating aerosol into the nose – using fast and small impulses, the drug mist can also penetrate the paranasal sinuses (refer also to Aerosol Journal Today 1/2009 p.6).
Quelle: Mainz et al. 2010 J Cyst Fibr 9(suppl 1): S23